Matt Kapusta, uniQure CEO
UniQure sells part of Hemgenix royalty for $400M cash
UniQure sold part of its lucrative Hemgenix royalty rights to a pair of investment firms for up to $400 million in cash.
The Dutch biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
